With Halloween coming up soon, I thought I’d reflect on some of the things I find scary about the industry.

One of them is how many sponsor organizations still expect patients to be recruited into their trials without doing anything particular to promote them.

Another is the sense that patients should somehow be grateful for the chance to participate. When in reality the gratitude should be flowing towards the patients – who are, after all, giving of their time and physiology to trial an unproven treatment – which would certainly be helpful for keeping them engaged.

Some of the processes that the research sites are forced to get to grips with are equally scary, and certainly don’t lend themselves to a smooth patient journey through a trial.

And perhaps scariest of all is the high level of patient burden that features in so many trial protocols, that is seemingly designed to ensure nobody becomes interested in taking part.

You may also like

Biotech C-suites Should keep Patient Recruitment in Mind from the Outset
In biotech, a strong C-suite isn’t just about job titles - it’s about covering every part of the journey from discovery to delivery. Including being prepared to tackle one of the biggest ...
Key C-suite Roles for Biotech Success - The Chief Patient Recruitment Officer (CPRO)
While biotech companies have built C-suites with scientific, medical, financial, operational, and business expertise, a critical function has remained conspicuously absent - addressing one ...
Key C-suite Roles for Biotech Success - The Chief Business Officer (CBO)
The Chief Business Officer leads external strategy - licensing deals, identifying pharma partnerships, and developing long-term growth planning and market positioning strategies that ...